Related references
Note: Only part of the references are listed.A comparison of Campath and Thymoglobulin as part of the conditioning before allogeneic hematopoietic stem cell transplantation
Anna-Carin Norlin et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2011)
Donor Lymphocyte Infusions Modulate Relapse Risk in Mixed Chimeras and Induce Durable Salvage in Relapsed Patients After T-Cell-Depleted Allogeneic Transplantation for Hodgkin's Lymphoma
Karl S. Peggs et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
T-cell-depleted allogeneic transplant without donor leukocyte infusions results in excellent long-term survival in patients with multiply relapsed Lymphoma. Predictors for survival after transplant relapse
Vaishalee P. Kenkre et al.
LEUKEMIA & LYMPHOMA (2011)
Outcome following Reduced-Intensity Allogeneic Stem Cell Transplantation (RIC AlloSCT) for Relapsed and Refractory Mantle Cell Lymphoma (MCL): A Study of the British Society for Blood and Marrow Transplantation
Gordon Cook et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2010)
Consensus Conference on Clinical Practice in Chronic Graft-versus-Host Disease (GVHD): First-Line and Topical Treatment of Chronic GVHD
Daniel Wolff et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2010)
HLA-mismatched unrelated donors are a viable alternate graft source for allogeneic transplantation following alemtuzumab-based reduced-intensity conditioning
Adam J. Mead et al.
BLOOD (2010)
Impact of in vivo alemtuzumab dose before reduced intensity conditioning and HLA-identical sibling stem cell transplantation: pharmacokinetics, GVHD, and immune reconstitution
Ronjon Chakraverty et al.
BLOOD (2010)
Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial
Peter Dreger et al.
BLOOD (2010)
Alemtuzumab is safe and effective as immunosuppressive treatment for aplastic anaemia and single-lineage marrow failure: a pilot study and a survey from the EBMT WPSAA
Antonio Maria Risitano et al.
BRITISH JOURNAL OF HAEMATOLOGY (2010)
Factors predicting long-term survival after T-cell depleted reduced intensity allogeneic stem cell transplantation for acute myeloid leukemia
Charles Craddock et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2010)
Immune reconstitution and cytomegalovirus infection after allogeneic stem cell transplantation: the important impact of in vivo T cell depletion
Martin Schmidt-Hieber et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2010)
T-Cell-Depleted Reduced-Intensity Transplantation Followed by Donor Leukocyte Infusions to Promote Graft-Versus-Lymphoma Activity Results in Excellent Long-Term Survival in Patients With Multiply Relapsed Follicular Lymphoma
Kirsty J. Thomson et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Reduced Mortality after Allogeneic Hematopoietic-Cell Transplantation.
Ted A. Gooley et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Incidence and Dynamics of Epstein-Barr Virus Reactivation After Alemtuzumab-Based Conditioning for Allogeneic Hematopoietic Stem-Cell Transplantation
Ben Carpenter et al.
TRANSPLANTATION (2010)
Two Hundred Living Donor Kidney Transplantations Under Alemtuzumab Induction and Tacrolimus Monotherapy: 3-Year Follow-Up
H. P. Tan et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2009)
BK Virus Infection Is Associated with Hematuria and Renal Impairment in Recipients of Allogeneic Hematopoetic Stem Cell Transplants
Peter H. O'Donnell et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2009)
Alemtuzumab as Treatment of Steroid-Refractory Acute Graft-versus-Host Disease: Results of a Phase II Study
Carmen Martinez et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2009)
Fludarabine-Melphalan Conditioning for AML and MDS: Alemtuzumab Reduces Acute and Chronic GVHD without Affecting Long-Term Outcomes
Koen Van Besien et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2009)
Successful Treatment of Severe Acute Intestinal Graft-versus-Host Resistant to Systemic and Topical Steroids with Alemtuzumab
Marc Schnitzler et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2009)
A Novel GVHD-Prophylaxis with Low-Dose Alemtuzumab in Allogeneic Sibling or Unrelated Donor Hematopoetic Cell Transplantation: The Feasibility of Deescalation
Hartmut Bertz et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2009)
Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation
Ola Landgren et al.
BLOOD (2009)
Response and toxicity of donor lymphocyte infusions following T-cell depleted non-myeloablative allogeneic hematopoietic SCT from 3-6/6 HLA matched donors
D. A. Rizzieri et al.
BONE MARROW TRANSPLANTATION (2009)
Salvage transplantation for allograft failure using fludarabine and alemtuzumab as conditioning regimen
J. Bolanos-Meade et al.
BONE MARROW TRANSPLANTATION (2009)
Reduced-intensity conditioning for severe aplasia using fludarabine and CY followed by infusion of ex vivo T-cell-depleted grafts leads to excellent engraftment and absence of GVHD
N. Novitzky et al.
BONE MARROW TRANSPLANTATION (2009)
Alemtuzumab markedly reduces chronic GVHD without affecting overall survival in reduced-intensity conditioning sibling allo-SCT for adults with AML
R. K. Malladi et al.
BONE MARROW TRANSPLANTATION (2009)
Rediscovering alemtuzumab: current and emerging therapeutic roles
John G. Gribben et al.
BRITISH JOURNAL OF HAEMATOLOGY (2009)
Favorable outcomes with alemtuzumab-conditioned unrelated donor stem cell transplantation in adults with high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in first complete remission
Bella Patel et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2009)
Imbalance of effector and regulatory CD4 T cells is associated with graft-versus-host disease after hematopoietic stem cell transplantation using a reduced intensity conditioning regimen and alemtuzumab
Katie Matthews et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2009)
Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model
Yanping Hu et al.
IMMUNOLOGY (2009)
Favorable Long-Term Survival After Reduced-Intensity Allogeneic Transplantation for Multiple-Relapse Aggressive Non-Hodgkin's Lymphoma
Kirsty J. Thomson et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Patterns and kinetics of T-cell chimerism after allo transplant with alemtuzumab-based conditioning: mixed chimerism protects from GVHD, but does not portend disease recurrence
Koen van Besien et al.
LEUKEMIA & LYMPHOMA (2009)
Allogeneic stem cell transplantation with alemtuzumab-based conditioning for patients with advanced chronic myelogenous leukemia
Xavier Poire et al.
LEUKEMIA & LYMPHOMA (2009)
Results of a phase I/II British Society of Bone Marrow Transplantation study on PCR-based pre-emptive therapy with valganciclovir or ganciclovir for active CMV infection following alemtuzumab-based reduced intensity allogeneic stem cell transplantation
Z. Y. Lim et al.
LEUKEMIA RESEARCH (2009)
Allogeneic Hematopoietic Stem-Cell Transplantation for Sickle Cell Disease.
Matthew M. Hsieh et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Homeostatic repopulation by CD28-CD8+ T cells in alemtuzumab-depleted kidney transplant recipients treated with reduced immunosuppression
P. Trzonkowski et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2008)
CD4+CD25+FOXP3+ regulatory t cells increase De novo in kidney transplant patients after immunodepletion with Campath-1H
D. D. Bloom et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2008)
Alemtuzumab for the treatment of steroid-refractory acute graft-versus-host disease
David Gomez-Almaguer et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2008)
Alemtuzumab-induced resolution of refractory cutaneous chronic graft-versus-host disease
Guillermo J. Ruiz-Arguelles et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2008)
Allogeneic transplants in follicular lymphoma: Higher risk of disease progression after reduced-intensity compared to myeloablative conditioning
Parameswaran Hari et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2008)
Post-transplant lymphoproliferative disease following reduced intensity conditioning transplants incorporating alemtuzumab
S. W. Bokhari et al.
BONE MARROW TRANSPLANTATION (2008)
Immunohematopoietic stem cell transplantation: introduction and 35 years of development in South Africa - the historical and scientific perspective
P. Jacobs et al.
BONE MARROW TRANSPLANTATION (2008)
Superiority of reduced-intensity allogeneic transplantation over conventional treatment for relapse of Hodgkin's lymphoma following autologous stem cell transplantation
K. J. Thomson et al.
BONE MARROW TRANSPLANTATION (2008)
Graft-versus-host disease following marrow transplantation for aplastic anemia: different impact of two GVHD prevention strategies
D. Siegal et al.
BONE MARROW TRANSPLANTATION (2008)
Outcomes following 50 mg versus 100 mg alemtuzumab in reduced-intensity conditioning stem cell transplants for acute myeloid leukaemia and poor risk myelodysplasia
Eleni Tholouli et al.
BRITISH JOURNAL OF HAEMATOLOGY (2008)
Outcome of BEAM-autologous and BEAM-alemtuzumab allogeneic transplantation in relapsed advanced stage follicular lymphoma
Wendy Ingram et al.
BRITISH JOURNAL OF HAEMATOLOGY (2008)
Alemtuzumab vs. Interferon beta-1a in early multiple sclerosis
Alasdair J. Coles et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Serotherapy with thymoglobulin and alemtuzumab differentially influences frequency and function of natural killer cells after allogeneic stem cell transplantation
O. Penack et al.
BONE MARROW TRANSPLANTATION (2008)
Outcomes of patients with AML and MDS who relapse or progress after reduced intensity allogeneic hematopoietic cell transplantation
D. A. Pollyea et al.
BONE MARROW TRANSPLANTATION (2007)
Fludarabine-based conditioning secures engraftment of second hematopoietic stem cell allografts (HSCT) in the treatment of initial graft failure
Joseph H. Chewning et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2007)
Reduced-intensity conditioning for allogeneic haematopoietic stem cell transplantation in relapsed and refractory Hodgkin lymphoma: impact of alemtuzumab and donor lymphocyte infusions on long-term outcomes
Karl S. Peggs et al.
BRITISH JOURNAL OF HAEMATOLOGY (2007)
Delayed attainment of full donor chimaerism following alemtuzumab-based reduced-intensity conditioning haematopoeitic stem cell transplantation for acute myeloid leukaemia and myelodysplastic syndromes is associated with improved outcomes
Zi Yi Lim et al.
BRITISH JOURNAL OF HAEMATOLOGY (2007)
Partially matched, nonmyeloablative allogeneic transplantation: Clinical outcomes and immune reconstitution
David A. Rizzieri et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Population pharmacokinetics-pharmacodynamics of alemtuzumab (Campath (R)) in patients with chronic lymphocytic leukaemia and its link to treatment response
D. R. Mould et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2007)
Heterogeneous CD52 expression among hematologic neoplasms: Implications for the use of alemtuzumab (CAMPATH-1H)
Scott J. Rodig et al.
CLINICAL CANCER RESEARCH (2006)
Pharmacokinetics of alemtuzumab after haploidentical HLA-mismatched hematopoietic stem cell transplantation using in vivo alemtuzumab with or without CD52-positive malignancies
Kumi Oshima et al.
AMERICAN JOURNAL OF HEMATOLOGY (2006)
Outcomes of alemtuzumab-based reduced intensity conditioning stem cell transplantation using unrelated donors for myelodysplastic syndromes
Zi Yi Lim et al.
BRITISH JOURNAL OF HAEMATOLOGY (2006)
Long-term follow-up of myeloablative allogeneic stem cell transplantation using Campath 'in the bag' as T-cell depletion: the Leiden experience
RMY Barge et al.
BONE MARROW TRANSPLANTATION (2006)
Subcutaneous alemtuzumab vs ATG in adjusted conditioning for allogeneic transplantation:: influence of Campath dose on lymphoid recovery, mixed chimerism and survival
G Juliusson et al.
BONE MARROW TRANSPLANTATION (2006)
Results of alemtuzumab-based reduced-intensity allogeneic transplantation for chronic lymphocytic leukemia: a British Society of Blood and Marrow Transplantation Study
J Delgado et al.
BLOOD (2006)
Pre-transplant ganciclovir and post transplant high-dose valacyclovir reduce CMV infections after alemtuzumab-based conditioning
J Kline et al.
BONE MARROW TRANSPLANTATION (2006)
Allogeneic stem-cell transplantation using a reduced-intensity conditioning regimen has the capacity to produce durable remissions and long-term disease-free survival in patients with high-risk acute myeloid leukemia and myelodysplasia
S Tauro et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Cytomegalovirus (CMV) infections and CMV-specific cellular immune reconstitution following reduced intensity conditioning allogeneic stem cell transplantation with alemtuzumab
R Lamba et al.
BONE MARROW TRANSPLANTATION (2005)
Outcomes of reduced-intensity transplantation for chronic myeloid leukemia: an analysis of prognostic factors from the Chronic Leukemia Working Party of the EBMT
C Crawley et al.
BLOOD (2005)
CAMPATH: from concept to clinic
H Waldmann et al.
PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY B-BIOLOGICAL SCIENCES (2005)
Fludarabine, melphalan, and alemtuzumab conditioning in adults with standard-risk advanced acute myeloid leukemia and myelodysplastic syndrome
K van Besien et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Comparison between antithymocyte globulin and alemtuzumab and the possible impact of KIR-ligand mismatch after dose-reduced conditioning and unrelated stem cell transplantation in patients with multiple myeloma
N Kröger et al.
BRITISH JOURNAL OF HAEMATOLOGY (2005)
Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma:: an analysis of prognostic factors from the Chronic Leukaemia Working Party of the EBMT
C Crawley et al.
BLOOD (2005)
Alemtuzumab induces enhanced apoptosis in vitro in B-cells from patients with chronic lymphocytic leukemia by antibody-dependent cellular cytotoxicity
H Nückel et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2005)
Immunocompetent T-cells with a memory-like phenotype are the dominant cell type following antibody-mediated T-cell depletion
JP Pearl et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2005)
FCGR3A and FCGR2A polymorphisms may not correlate with response to alemtuzumab in chronic lymphocytic leukemia
TS Lin et al.
BLOOD (2005)
Outcome following alemtuzumab (CAMPATH-1H)-containing reduced intensity allogeneic transplant regimen for relapsed and refractory non-Hodgkin's lymphoma (NHL)
E Morris et al.
TRANSFUSION AND APHERESIS SCIENCE (2005)
Dose-escalated donor lymphocyte inftisions following reduced intensity transplantation: toxicity, chimerism, and disease responses
KS Peggs et al.
BLOOD (2004)
BEAM-alemtuzumab reduced-intensity allogeneic stem cell transplantation for lymphoproliferative diseases: GVHD, toxicity, and survival in 65 patients
RD Faulkner et al.
BLOOD (2004)
Reduced-intensity allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myeloid leukemia with multilineage dysplasia using fludarabine, busulphan, and alemtuzumab (FBC) conditioning
AYL Ho et al.
BLOOD (2004)
Free circulating soluble CD52 as a tumor marker in chronic lymphocytic leukemia and its implication in therapy with anti-CD52 antibodies
M Albitar et al.
CANCER (2004)
Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration
G Hale et al.
BLOOD (2004)
Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma
E Morris et al.
BLOOD (2004)
Myeloablative allogeneic hematopoietic stem cell transplantation in patients who experience relapse after autologous stem cell transplantation for lymphoma: a report of the International Bone Marrow Transplant Registry
CO Freytes et al.
BLOOD (2004)
Rituximab and alemtuzumab induce a nonclassic, caspase-independent apoptotic pathway in B-lymphoid cell lines and in chronic lymphocytic leukemia cells
M Stanglmaier et al.
ANNALS OF HEMATOLOGY (2004)
Phase II study of alerntuzurnab in chronic lymphoproliferative disorders
A Ferrajoli et al.
CANCER (2003)
Reconstitution of the Epstein-Barr virus-specific cytotoxic T-lymphocyte response following T-cell-depleted myeloablative and nonmyeloablative allogeneic stem cell transplantation
S Chakrabarti et al.
BLOOD (2003)
Pharmacokinetics of alemtuzumab used for in vivo and in vitro T-cell depletion in allogeneic transplantations: relevance for early adoptive immunotherapy and infectious complications
EC Morris et al.
BLOOD (2003)
T-cell depletion with Campath-1H 'in the bag' for matched related allogeneic peripheral blood stem cell transplantation is associated with reduced graft-versus-host disease, rapid immune constitution and improved survival
S Chakrabarti et al.
BRITISH JOURNAL OF HAEMATOLOGY (2003)
Differential CD52 expression by distinct myeloid dendritic cell subsets: implications for alemtuzumab activity at the level of antigen presentation in allogeneic graft-host interactions in transplantation
G Ratzinger et al.
BLOOD (2003)
Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation
SP Robinson et al.
BLOOD (2002)
Adenovirus infections following allogeneic stem cell transplantation: incidence and outcome in relation to graft manipulation, immunosuppression, and immune recovery
S Chakrabarti et al.
BLOOD (2002)
High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution
S Chakrabarti et al.
BLOOD (2002)
Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen
R Chakraverty et al.
BLOOD (2002)
Campath-1H treatment of T-cell prolymphocytic leukemia in patients for whom at least one prior chemotherapy regimen has failed
MJ Keating et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
The history and future of T-cell depletion as graft-versus-host disease prophylaxis for allogeneic hematopoietic stem cell transplantation
VT Ho et al.
BLOOD (2001)
Pharmacokinetics of CAMPATH-1H in BMT patients
P Rebello et al.
CYTOTHERAPY (2001)
Share Paper
